An In-Depth Overview of Interstitial Lung Diseases for Healthcare Professionals
OthersPage Navigation
Introduction
Interstitial lung diseases (ILDs) represent a heterogeneous group of over 200 chronic lung disorders. They are characterized by inflammation and fibrosis of the pulmonary interstitium, leading to progressive dyspnea and impaired oxygen transport.
Classification and Etiology
ILDs can be classified into idiopathic and secondary forms. Idiopathic pulmonary fibrosis is the most common form, with unknown etiology. Secondary ILDs can be due to connective tissue diseases, occupational and environmental exposures, drug toxicity, or radiation therapy.
Clinical Presentation and Diagnosis
Patients typically present with progressive exertional dyspnea and non-productive cough. Diagnostic evaluation includes high-resolution computed tomography and sometimes lung biopsy. Pulmonary function tests often show a restrictive pattern with reduced diffusion capacity.
Management
Management strategies include treating the underlying cause, supportive care, and in some cases, lung transplantation. Pharmacological therapy includes anti-fibrotic agents, immunosuppressants, and in certain cases, anticoagulants.
Prognosis
Prognosis varies widely, depending on the specific ILD. Generally, idiopathic forms have a poor prognosis, with a median survival of 2-3 years from diagnosis.
Conclusion
Early recognition and appropriate management of ILDs can improve quality of life and potentially slow disease progression. Continuing research is needed to further understand the pathophysiology and to develop more effective treatments.
Recommended News For You
Recommended Articles For You
Featured News
Featured Articles
Featured Events
Featured KOL Videos
1.
Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing
2.
Q&A: Why adolescents and young adults with cancer are falling behind
3.
Fixed-Duration Combo Shows Promise for Relapsed MCL
4.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
5.
A study has developed molecular markers that predict meningioma recurrence.
1.
Ultimate Guide to Oncology Services in the USA
2.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
5.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on the First Line Management of ALK+ NSCLC
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Welcome to Hidoc Dr.
Join to enhance your clinical skills and gain specialized in-depth medical knowledge